Back pain app developer Kaia Health nets $10M in series A round

A senior woman sitting on a yoga mat looks at a smartphone with information about heart rate.
Chronic back pain is estimated to affect 100 million people in the U.S. annually, and is the number one reason why people are prescribed painkillers, according to Kaia. (Getty Images/doble-d)

Kaia Health, makers of smartphone apps to support in-home treatment of chronic conditions, has raised $10 million in funding to help support its U.S. rollout.

The series A round, led by Balderton Capital, will help the London- and Munich-based company open a new office in New York City and fund additional clinical studies of digital therapeutics aimed at more indications.

Its back pain app uses a smartphone’s motion-tracking technology to offer users real-time feedback in a variety of daily exercises, as well as relaxation techniques and education, and is currently offered free of charge by some European health insurance companies.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

Meanwhile, its app focused on chronic obstructive pulmonary disorder recently demonstrated it could help reduce symptoms through cardiovascular and muscle exercises in a pilot study, tailored through algorithms based on each user’s performance.

Patients can also contact a coach through the app, and access information on breathing and coughing techniques as well as nutrition and medication tracking. While that app is currently available in German, the company plans to translate it into English and other languages.

Chronic back pain is estimated to affect 100 million people in the U.S. annually, and it is the No. 1 reason why people are prescribed painkillers, according to Kaia. Meanwhile, in the U.K., about 30% of all general practitioner appointments are related to musculoskeletal pain.

“Over the last 12 months, we’ve demonstrated a universal, unmet need for affordable and accessible digital therapy products, such as our world’s first computer vision-powered back pain app,” said Konstantin Mehl, co-founder and CEO of Kaia Health. “These improve treatment paths for patients and reduce costs for payers in healthcare around the globe.”

Suggested Articles

Flagship Pioneering has raised $824 million for a fund to support biotech and health companies that have come up through its Flagship Labs foundry.

The FDA’s warning letters to breast implant manufacturers come during newly galvanized agency probes into the long-term safety of silicone implants.

At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis